945042 Establishing international standars in the analysis of patient reported outcomes and health related quality of life daa in cancer clinical trials (SISAQOL-IMI)

SISAQOL-IMI
SISAQOL-IMI
Proyectos Internacionales
Unidad de gestión de proyectos
945042 Establishing international standars in the analysis of patient reported outcomes and health related quality of life daa in cancer clinical trials (SISAQOL-IMI)

SISAQOL-IMI (Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials – IMI) is an international multidisciplinary consortium, co-led by the European Organization for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI). The consortium has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient reported outcome (PRO) data in cancer clinical trials.

SISAQOL-IMI will establish guidance on how to use patient-reported outcomes in cancer clinical trials so that they can be used in a methodologically sound way, analysed in a statistically adequate manner, and intelligibly presented to ensure a high study quality and a better comparability of results across clinical trials.

Web
Organismo financiador
Ficha técnica
Financiación
Internacional
Organismo
European Commission
Inicio - Fin
-
Centro al que pertenece
Fundación Pública Miguel Servet
Investigadores/as